IDEAS home Printed from https://ideas.repec.org/p/hal/journl/hal-00749148.html
   My bibliography  Save this paper

The future of drug discovery and development: Shifting emphasis towards personalized medicine

Author

Listed:
  • Arsia Amir Aslani

    (Global Health - MTS - Management Technologique et Strategique - EESC-GEM Grenoble Ecole de Management)

  • Vincent Mangematin

    (Global Health - MTS - Management Technologique et Strategique - EESC-GEM Grenoble Ecole de Management)

Abstract

The drug discovery sector is being revolutionized by the current rate of advances in the public and private human genome projects and by the development of new technologies for biomarker testing. In effect, as the genetic roots of disease, disease progression and treatment effectiveness are uncovered, the demand for sophisticated prognostic, diagnostic and monitoring tests will be increasing. Already this has led to the development of innovative diagnostics products meeting the criteria of improved efficacy and safety as well as better cost-benefits. In order to achieve the ultimate goal of a more predictive and personalized medicine requires the drug discovery industry to implement more synergies between the two worlds of clinical research and diagnostics. The therapeutics that are enabled by that strategy are often called "theranostics" -- highly specific tests that allow for the diagnosis of the disease, but to administer the most appropriate treatment regimen, and to monitor a patient's response to therapy. Biomarkers will constitute a critical component of the health care delivery system in order to detect, diagnose and monitor diseases and other medical conditions as well as to evaluate treatment options and effectiveness. While diagnostic breakthroughs typically precede therapeutic advances, the presence of new therapies can stimulate the demand for testing. The main question that remains to be answered is how will the biomarker paradigm alters these companies' innovation and commercialization strategies. Whereas developing drug targets may offer greater long-term value, initial commercial opportunities often arise in diagnostics.

Suggested Citation

  • Arsia Amir Aslani & Vincent Mangematin, 2010. "The future of drug discovery and development: Shifting emphasis towards personalized medicine," Post-Print hal-00749148, HAL.
    • Handle: RePEc:hal:journl:hal-00749148
    DOI: 10.1016/j.techfore.2009.09.005
    as

    Download full text from publisher

    To our knowledge, this item is not available for download. To find whether it is available, there are three options:
    1. Check below whether another version of this item is available online.
    2. Check on the provider's web page whether it is in fact available.
    3. Perform a search for a similarly titled item that would be available.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Ávila-Robinson, Alfonso & Islam, Nazrul & Sengoku, Shintaro, 2019. "Co-evolutionary and systemic study on the evolution of emerging stem cell-based therapies," Technological Forecasting and Social Change, Elsevier, vol. 138(C), pages 324-339.
    2. Aaldering, Lukas Jan & Leker, Jens & Song, Chie Hoon, 2019. "Uncovering the dynamics of market convergence through M&A," Technological Forecasting and Social Change, Elsevier, vol. 138(C), pages 95-114.
    3. Alon, Ido & Guimón, José & Urbanos-Garrido, Rosa, 2019. "What to expect from assisted reproductive technologies? Experts' forecasts for the next two decades," Technological Forecasting and Social Change, Elsevier, vol. 148(C).
    4. Lauto, Giancarlo & Valentin, Finn, 2016. "The knowledge production model of the New Sciences: The case of Translational Medicine," Technological Forecasting and Social Change, Elsevier, vol. 111(C), pages 12-21.
    5. Alfonso Ávila-Robinson & Cristian Mejia & Shintaro Sengoku, 2021. "Are bibliometric measures consistent with scientists’ perceptions? The case of interdisciplinarity in research," Scientometrics, Springer;Akadémiai Kiadó, vol. 126(9), pages 7477-7502, September.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:hal:journl:hal-00749148. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: CCSD (email available below). General contact details of provider: https://hal.archives-ouvertes.fr/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.